Arvinas (ARVN) Insider JR. Buys 15,527 Shares

Kennedy Edward Moore JR. recently acquired 22,714 shares of Arvinas, Inc. (NasdaqGS: ARVN) on June 24, 2026. The transaction was not part of a planned trading program, indicating a direct purchase by the insider.

Insider Buying and Selling at Arvinas, Inc.

On June 24, 2026, several insiders, including Kennedy Edward Moore JR., made significant purchases of Arvinas shares. Bain Linda bought 22,714 shares, while Smaldone Alsup Laurie and Norwalk Leslie each acquired 15,527 shares. Morrison Briggs also made two purchases, totaling 38,241 shares.

Other Institutional Activity in Arvinas, Inc.

In recent institutional activity, BlackRock, Inc. trimmed its holdings by 524,917 shares, leaving it with 6,797,584 shares valued at about $72.1 million. Vanguard Portfolio Management LLC opened a new position with 3,889,628 shares worth approximately $41.2 million. D. E. Shaw & Co., Inc. reduced its stake by 50,634 shares, maintaining 3,638,567 shares valued at $38.6 million. TCG Crossover Management, LLC decreased its holdings by 278,755 shares, ending with 2,387,461 shares worth about $25.3 million.

Arvinas, Inc. Stock Down 3.5%

Shares of Arvinas, Inc. traded near $8.03 on Saturday. The biotechnology company has a market cap of $518.1 million. It is not currently profitable, so it has no meaningful forward P/E ratio. The stock's 52-week range spans from $6.06 to $14.51, with a 50-day moving average of $9.08 and a 200-day moving average of $10.67. Arvinas maintains a strong liquidity position with a current ratio of 5.44 and a quick ratio of 5.36.

Recent Earnings

Arvinas reported revenue of $89.4 million with a decline in revenue growth of 91.7%. The company posted a net margin of -247.5% and a return on equity of -42.3%. Investors can look forward to the next earnings report on August 5, 2026.

Analysts Set New Price Targets

On June 3, 2026, Stephens & Co. reiterated its 'buy' rating on Arvinas with a price target of $18. Barclays maintained a 'buy' rating with a $20 target on May 13, 2026. BTIG also kept a 'buy' rating and set an $18 target. The analyst consensus suggests a 'buy' recommendation, with a mean price target of $14.8 across 15 analyst opinions.

About Arvinas, Inc.

Arvinas, Inc. is a clinical-stage biotechnology company based in New Haven, Connecticut. It focuses on developing therapies that degrade disease-causing proteins using its proprietary PROTAC technology. The company is working on various clinical development programs targeting neurodegenerative diseases and cancers. Arvinas collaborates with major pharmaceutical companies like Pfizer and Genentech.

Bottom Line

Kennedy Edward Moore JR.'s recent purchase of Arvinas shares highlights insider confidence in the company's potential. Arvinas, a player in the biotechnology sector, continues to attract attention with its innovative approach to protein degradation. While the company is not yet profitable, analysts remain optimistic about its future prospects, as reflected in recent 'buy' ratings.